Navigation Links
Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
Date:5/19/2011

SAN FRANCISCO and SEATTLE, May 19, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.  The preliminary data from the study HEP007 indicated that the risk of death for patients who received JX-594 at the high therapeutic dose was markedly reduced by more than 50 percent (hazard ratio < 0.5) when compared to patients randomized to a control low dose (one-tenth of the high dose). Clinical investigators enrolled approximately 30 patients at sites in the United States, Canada and South Korea.

The data were presented by David Kirn, M.D., president and chief executive officer of Jennerex, today in an oral presentation in the Presidential Symposium of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Seattle, Washington.  These data were also chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.  Jennerex and its partners expect to present further follow-up on the complete trial data set at a medical conference later this year.

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib-(Nexavar®) treatment is planned for initiation in the second half of this year; this trial (TRAVERSE), conducted globally with Jennerex's partners, will evaluate survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"We are extremely encouraged by the promising overall survival results presented today. These results are consistent with a clinically meaningful survival benefit in patients wit
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
(Date:12/19/2014)... 18, 2014 LayerBio is an MIT ... wound care. The National Eye Institute (NEI) at the ... Phase I SBIR grant to develop a drug-eluting intraocular ... most common cause of vision loss in people over ... According to Dr. Ken Mandell, LayerBio’s Founder and CEO, ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... to the rising ageing population and technological innovations ... and nutraceutical industries are catalysing the growth of ... @ http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report ... as well as new entrants/smaller firms to gauge ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
... 2010 Cephalon, Inc. (Nasdaq: CEPH ) ... Chief Executive Officer, Frank Baldino, Jr., Ph.D. passed away ... biotechnology industry, he was an inspirational leader who will ... and extends its sympathies to the entire Baldino family. Media ...
... SALT LAKE CITY, Dec. 16, 2010 ... may become the world,s tiniest computer memory: magnetic "spins" in the centers ... electronically a big step toward using the new kind of memory ... "The length of ...
... DENVER, Dec. 16, 2010 BioSpace launched ... showcasing life sciences companies across Massachusetts. (Logo: ... science employers. Each campaign participant,s logo is added to ... promoted online and at industry events or career fairs. ...
Cached Biology Technology:Computer memory takes a spin 2Computer memory takes a spin 3Computer memory takes a spin 4Computer memory takes a spin 5BioSpace Highlights One of the Nation's Largest Life Science Regions 2
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... program that trains emergency medical service technicians (EMS) to read ... and expedite treatment for the severe heart condition known as ... attack, has excellent results and should become the standard of ... of the Canadian Journal of Cardiology . ...
... cells organized in thousands of small divots. Hit these cells ... candidate for a cancer drug. But a review published this ... argues that these 2D models in fact offer very ... and may often give researchers misleading results. "Up ...
... scientific research has deep roots in the history of ... off spectacularly from launch pads across the disciplines of ... and a sea change in a scientific culture now ... science, crowd-sourced science, DIY research, volunteer monitoring, community participatory ...
Cached Biology News:ECGs administered by paramedics can speed treatment for severe heart attacks 2ECGs administered by paramedics can speed treatment for severe heart attacks 33-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3Inaugural cross-disciplinary Public Participation in Scientific Research conference 2
Rabbit polyclonal to Vitronectin ( Abpromise for all tested applications). Antigen: Full length native Vitronectin (Cow) Entrez Gene ID: 7448 Swiss Protein ID: P04004...
... miRCURY LNA technology enables sensitive and specific ... hybridisation. miRCURY LNA in situ detection probes ... the specific and sensitive detection of miRNAs. ... possible in whole mounts, thin sections, single ...
... Roches RTS AviTag E. coli Biotinylation Kit, ... 100 and 500 E. coli expression kits. (Cat. ... 335 461). This kit provides vectors for the ... peptide sequence. The expressed protein can be enzymatically ...
... The EZ DNA Methylation Kit uses a ... for DNA methylation analysis. The kit is ... takes place between cytosine and sodium bisulfite ... EZ DNA Methylation Kits innovative in-column desulphonation ...
Biology Products: